Lung TransplantNCT05898776
10°C vs 4°C Lung Preservation RCT
A study testing Lung transplantation after 10°C donor lung preservation and Lung transplantation after standard ice cooler donor lung preservation in people with Lung Transplant and Organ Preservation, run by University Health Network, Toronto at 17 sites in 8 countries.
Trial summary
Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting ~25%… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Lung Transplant, Organ Preservation
- What is being tested?
- Lung transplantation after 10°C donor lung preservation and Lung transplantation after standard ice cooler donor lung preservation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 317 participants
- Where
- 17 sitesin 8 countries
- Study dates
- 9 Jun 2023to 22 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Donor Inclusion Criteria
- Donation after brain death (DBD) or donation after cardiac death (DCD)
- Donor lungs are suitable to go straight to LTx (i.e., do not need ex vivo lung perfusion (EVLP) assessment)
Donor Exclusion Criteria
- Concerns with organ preservation technique
- Need for EVLP assessment
Recipient Inclusion Criteria
- 18-80 years old
- Primary lung transplantation
- Bilateral lung transplantation
Recipient Exclusion Criteria
- Re-transplantation
- Multi-organ transplantation
- Single lung transplantation
- Participation in a contraindicating trial
Trial locations and contacts
17 sites in 8 countries.
17 sites in 8 countries
United States7 sites
University of Miami
Coral Gables, Florida, 33146
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Corewell Health Research Institute
Grand Rapids, Michigan, 49503
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
Dignity Health (St. Joseph's Hospital and Medical Center)
Phoenix, Arizona, 85050
Mayo Clinic
Rochester, Minnesota, 55905
University of California San Francisco
San Francisco, California, 94143
Canada2 sites
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, H2X0A9
University Health Network (Toronto General Hospital)
Toronto, Ontario, M5G 2C4
Spain2 sites
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital Universitario Puerta de Hierro-Majadahonda
Madrid
Switzerland2 sites
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne
University Hospital Zurich
Zurich
Australia1 site
St Vincent's Hospital Sydney Limited
Sydney, New South Wales, 2010
France1 site
The Saint Joseph Hospital Foundation (Hôpital Marie Lannelongue)
Paris, 75014
About this study
Official title: Safety of 10°C Lung Preservation vs. Standard of Care: A Multi-Centre Prospective Non-Inferiority Trial
Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting ~25% of lung transplant patients. Induced by ischemia reperfusion, PGD represents a severe and acute lung injury that occurs within the first 72 hours after transplantation, and has a significant impact on short- and long-term outcomes, and a significant increase in treatment costs. Any intervention that reduces the risk of PGD will lead to major improvements in short- and long-term transplant outcomes and health care systems.
One of the main strategies to reduce the risk and severity of post-transplant PGD is to improve pre-transplant donor lung preservation methods. In current practice, lung preservation is typically performed by cold flushing the organ with a specialized preservation solution, followed by subsequent hypothermic storage on ice (~4°C). This method continues to be used and applied across different organ systems due to its simplicity and low cost. Using this method for the preservation of donor lungs, the current maximum accepted preservation times have been limited to approximately 6-8h. While the goal of hypothermic storage is to sustain cellular viability during ischemic time through reduced cellular metabolism, lower organ temperature has also been shown to progressively favor mitochondrial dysfunction. Therefore, the ideal temperature for donor organ preservation remains to be defined and should maintain a balance between avoidance of mitochondrial dysfunction and prevention of cellular exhaustion. In addition to that, safe and longer preservation times can lead to multiple advantages such as moving overnight transplants to daytime, more flexibility to transplant logistics, more time for proper donor to recipient matching etc.
Read more
Building on pre-clinical research suggesting that 10°C may be the optimal lung storage temperature, a prospective, multi-center, non-randomized clinical trial was conducted at University Health Network, Medical University of Vienna and Puerta de Hierro Majadahonda University Hospital. Donor lungs meeting criteria for direct transplantation and with cross clamp times between 6:00pm - 4:00am were intentionally delayed to an earliest allowed start time of 6:00am and a maximum preservation time from donor cold flush to recipient anesthesia start time of 12 hours. Lungs were retrieved and transported in the usual fashion using a cooler with ice and transferred to a 10°C temperature-controlled cooler upon arrival to transplant hospital until implantation. The primary outcome of this study was incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, with secondary endpoints including: recipient time on the ventilator, ICU Length of Stay (LOS), hospital LOS, 30-day survival and lung function at 1-year. Outcomes were compared to a contemporaneous conventionally transplanted recipient cohort using propensity score matching at a 1:2 ratio. 70 patients were included in the study arm. Post-transplant outcomes were comparable between the two groups for up to 1 year. Thus, intentional prolongation of donor lung preservation at 10°C was shown to be clinically safe and feasible.
In the current study design, the investigators will conduct a multi-centre, non-inferiority, randomized, controlled trial of 300 participants to compare donor lung preservation from the time of explant to implant at ~10°C in X°Port Lung Transport Device (Traferox Technologies Inc.) vs a standard ice cooler. When eligible donor lungs become available for a consented recipient, the lungs will be randomized to undergo a preservation protocol using either 10°C (X°Port Lung Transport Device, Traferox Technologies Inc.) or standard of care. The primary outcome of the study is incidence of ISHLT Primary Graft Dysfunction Grade 3 at 72 hours. Post-transplant outcomes will be followed for one year.
- Conditions
- Lung Transplant, Organ Preservation
- Being tested
- Lung transplantation after 10°C donor lung preservation, Lung transplantation after standard ice cooler donor lung preservation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lung transplantation after 10°C donor lung preservationDevice
When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
Lung transplantation after standard ice cooler donor lung preservationDevice
When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
| Study group | Role | What they receive |
|---|---|---|
| 10°C lung preservation | Experimental | Not described Receives: Device: Lung transplantation after 10°C donor lung preservation |
| Standard lung preservation | Active comparator | Not described Receives: Device: Lung transplantation after standard ice cooler donor lung preservation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Primary Graft Dysfunction (PGD) Grade 3 as per International Society for Heart and Lung Transplantation (ISHLT)
PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.
Measured: 72 hours post-transplant
Secondary outcomes (7)
Incidence of Primary Graft Dysfunction Grade 2-3 as per International Society for Heart and Lung Transplantation
PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.
Measured: 0 (ICU arrival), 24, 48, and 72 hours post-transplant
Time on ventilator
Measured: Index hospitalization (up to 1 year)
Total ICU and hospital length of stay
Measured: Index hospitalization (up to 1 year)
Overall survival
Measured: 30 days, 1 year post-transplant
Occurrence of acute rejection
Measured: 1 year post-transplant
Six minute walk test
Measured: 1 year post-transplant
Forced expiratory volume - one second (FEV1 in L)
Measured: 1 year post-transplant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2023
- Study start9 Jun 2023
- Primary completion24 Nov 2025
- Study completion22 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung TransplantStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 317 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Collaborators
- Medical University of Vienna, Vanderbilt University, Puerta de Hierro University Hospital, University of California, San Francisco, Centre Hospitalier Universitaire Vaudois, Mayo Clinic, St Vincent's Hospital, Sydney, University of Texas Southwestern Medical Center, Corewell Health West, University of Miami, University Hospital of Leuven Leuven, Centre hospitalier de l'Université de Montréal (CHUM), University Hospital, Zürich, Dignity Health, Hospital Universitario 12 de Octubre, Marie Lannelongue Hospital, Le Plessis Robinson, France
- Responsible party
- Sponsor
- Investigators
- Elliot Wakeam, MD MPH, Principal investigator, University Health Network, Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05898776
- Sponsor's protocol ID
- 22-5909
- Status last verified
- Mar 2026
- First submitted
- 31 May 2023
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety of 10°C Lung Preservation vs. Standard of Care: A Multi-Centre Prospective Non-Inferiority Trial
- ClinicalTrials.gov ID
- NCT05898776
- Acronym / sponsor ID
- 22-5909
- Conditions
- Lung Transplant, Organ Preservation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 317 participants (actual)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Collaborators
- Medical University of Vienna, Vanderbilt University, Puerta de Hierro University Hospital, University of California, San Francisco, Centre Hospitalier Universitaire Vaudois, Mayo Clinic, St Vincent's Hospital, Sydney, University of Texas Southwestern Medical Center, Corewell Health West, University of Miami, University Hospital of Leuven Leuven, Centre hospitalier de l'Université de Montréal (CHUM), University Hospital, Zürich, Dignity Health, Hospital Universitario 12 de Octubre, Marie Lannelongue Hospital, Le Plessis Robinson, France
- Study start
- 9 Jun 2023 (actual)
- Primary completion
- 24 Nov 2025 (actual)
- Study completion
- 22 Nov 2026 (estimated)
- First posted
- 12 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting ~25% of lung transplant patients. Induced by ischemia reperfusion, PGD represents a severe and acute lung injury that occurs within the first 72 hours after transplantation, and has a significant impact on short- and long-term outcomes, and a significant increase in treatment costs. Any intervention that reduces the risk of PGD will lead to major improvements in short- and long-term transplant outcomes and health care systems.
One of the main strategies to reduce the risk and severity of post-transplant PGD is to improve pre-transplant donor lung preservation methods. In current practice, lung preservation is typically performed by cold flushing the organ with a specialized preservation solution, followed by subsequent hypothermic storage on ice (~4°C). This method continues to be used and applied across different organ systems due to its simplicity and low cost. Using this method for the preservation of donor lungs, the current maximum accepted preservation times have been limited to approximately 6-8h. While the goal of hypothermic storage is to sustain cellular viability during ischemic time through reduced cellular metabolism, lower organ temperature has also been shown to progressively favor mitochondrial dysfunction. Therefore, the ideal temperature for donor organ preservation remains to be defined and should maintain a balance between avoidance of mitochondrial dysfunction and prevention of cellular exhaustion. In addition to that, safe and longer preservation times can lead to multiple advantages such as moving overnight transplants to daytime, more flexibility to transplant logistics, more time for proper donor to recipient matching etc.
Building on pre-clinical research suggesting that 10°C may be the optimal lung storage temperature, a prospective, multi-center, non-randomized clinical trial was conducted at University Health Network, Medical University of Vienna and Puerta de Hierro Majadahonda University Hospital. Donor lungs meeting criteria for direct transplantation and with cross clamp times between 6:00pm - 4:00am were intentionally delayed to an earliest allowed start time of 6:00am and a maximum preservation time from donor cold flush to recipient anesthesia start time of 12 hours. Lungs were retrieved and transported in the usual fashion using a cooler with ice and transferred to a 10°C temperature-controlled cooler upon arrival to transplant hospital until implantation. The primary outcome of this study was incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, with secondary endpoints including: recipient time on the ventilator, ICU Length of Stay (LOS), hospital LOS, 30-day survival and lung function at 1-year. Outcomes were compared to a contemporaneous conventionally transplanted recipient cohort using propensity score matching at a 1:2 ratio. 70 patients were included in the study arm. Post-transplant outcomes were comparable between the two groups for up to 1 year. Thus, intentional prolongation of donor lung preservation at 10°C was shown to be clinically safe and feasible.
In the current study design, the investigators will conduct a multi-centre, non-inferiority, randomized, controlled trial of 300 participants to compare donor lung preservation from the time of explant to implant at ~10°C in X°Port Lung Transport Device (Traferox Technologies Inc.) vs a standard ice cooler. When eligible donor lungs become available for a consented recipient, the lungs will be randomized to undergo a preservation protocol using either 10°C (X°Port Lung Transport Device, Traferox Technologies Inc.) or standard of care. The primary outcome of the study is incidence of ISHLT Primary Graft Dysfunction Grade 3 at 72 hours. Post-transplant outcomes will be followed for one year.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 10°C lung preservation | Experimental | Device: Lung transplantation after 10°C donor lung preservation |
| Standard lung preservation | Active comparator | Device: Lung transplantation after standard ice cooler donor lung preservation |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lung transplantation after 10°C donor lung preservationWhen suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries. | Device | 10°C lung preservation |
| Lung transplantation after standard ice cooler donor lung preservationWhen suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries. | Device | Standard lung preservation |
Primary outcome
Incidence of Primary Graft Dysfunction (PGD) Grade 3 as per International Society for Heart and Lung Transplantation (ISHLT)
Time frame: 72 hours post-transplant
PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.
7 secondary outcomes
Incidence of Primary Graft Dysfunction Grade 2-3 as per International Society for Heart and Lung Transplantation
Time frame: 0 (ICU arrival), 24, 48, and 72 hours post-transplant
Time on ventilator
Time frame: Index hospitalization (up to 1 year)
Total ICU and hospital length of stay
Time frame: Index hospitalization (up to 1 year)
Overall survival
Time frame: 30 days, 1 year post-transplant
Occurrence of acute rejection
Time frame: 1 year post-transplant
Six minute walk test
Time frame: 1 year post-transplant
Forced expiratory volume - one second (FEV1 in L)
Time frame: 1 year post-transplant
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
Related trials for Lung Transplant
RecruitingPhase 4
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Vaccination, Respiratory Syncytial Virus (RSV)
Active, not recruiting
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
Graft Vs Host Disease, Acute-graft-versus-host Disease
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
RecruitingPhase 3
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
RecruitingPhase 1
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
Lung Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elliot Wakeam, MD MPH principal investigator
University Health Network, Toronto
17 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lung transplantation after 10°C donor lung preservation and Lung transplantation after standard ice cooler donor lung preservation in people with Lung Transplant and Organ Preservation, run by University Health Network, Toronto at 17 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in United States, Canada, Spain, Switzerland, Australia and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Primary Graft Dysfunction (PGD) Grade 3 as per International Society for Heart and Lung Transplantation (ISHLT) (time frame: 72 hours post-transplant). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.